Predict your next investment

Government
cancer.gov

See what CB Insights has to offer

Investments

132

Portfolio Exits

17

Partners & Customers

10

About National Cancer Institute

The National Cancer Institute (NCI) is part of the National Institutes of Health (NIH), which is one of 11 agencies that compose the Department of Health and Human Services (HHS). The NCI, established under the National Cancer Institute Act of 1937, is the Federal Government's principal agency for cancer research and training. The National Cancer Act of 1971 broadened the scope and responsibilities of the NCI and created the National Cancer Program. Over the years, legislative amendments have maintained the NCI authorities and responsibilities and added new information dissemination mandates as well as a requirement to assess the incorporation of state-of-the-art cancer treatments into clinical practice.The National Cancer Institute coordinates the National Cancer Program, which conducts and supports research, training, health information dissemination, and other programs with respect to the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients.

National Cancer Institute Headquarter Location

6116 Executive Blvd Suite 300

Bethesda, Maryland, 20892,

United States

800-422-6237

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing National Cancer Institute

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find National Cancer Institute in 2 Expert Collections, including Pharma Startups.

P

Pharma Startups

5,090 items

Pharmaceutical companies working across drug discovery, drug development and drug manufacturing.

G

Genomics

391 items

Investors that invest in genomics AND have made at least 10 investments (across sectors) in the past 12 months

Latest National Cancer Institute News

UTHSC researcher receives funding to advance The Cancer Genome Atlas project

Sep 16, 2021

Neil Hayes, MD, MPH, director of the Center for Cancer Research at the University of Tennessee Health Science Center, is one of two principal investigators for a $1.8 million grant that extends the work of The Cancer Genome Atlas (TCGA), a groundbreaking multisite project to understand cancer at its molecular level through genome sequencing and extensive data analysis. The grant from the National Cancer Institute, which extends over five years, is a computational grant to continue to analyze the genetics of cancers, with many of the cases coming from patients treated in some of the most-important recent clinical trials, Dr. Hayes said. In this way, the new project advances the research beyond identification toward understanding interactions of cancer genetics and therapeutics, as measured through the samples. Related Stories Dr. Hayes, division chief of Hematology and Oncology at UTHSC, shares co-principal investigator duties with Katherine A. Hoadley, PhD, assistant professor at the University of North Carolina at Chapel Hill. The total funding for the project is split equally between the two universities. "This is the most-recent version of cancer genomics projects directly descended from TCGA," said Dr. Hayes, who was one of the investigators on The Cancer Genome Atlas, which began in 2006 and formally ended in 2018. A flagship team science effort of the National Institutes of Health and the National Human Genome Research Institute, The Cancer Genome Atlas has published findings identifying genomic changes or mutations in cells of 33 types of cancer by analyzing more than 20,000 specimens. Researchers from a dozen or more institutions across the country built a network to complete the project, and have published their findings in more than 200 papers in prestigious scientific journals. Dr. Hayes, the Van Vleet Endowed Professor in Medical Oncology at UTHSC, was a leader of a site at the University of North Carolina that conducted the sequencing of RNA, which controls abnormal genetic expressions in cancer cells. He was recruited to UTHSC in 2017. More than 15 years after his original work on the TCGA, he remains enthusiastic about the continued potential of cancer genomics in patient health. In the beginning, we were really out in the wilderness as far as the cancer genome. We were describing all kinds of abnormalities in human tissues that had transformed from normal to cancer. In many ways, it was a process of generating a list of all the ways in which a normal cell could go wrong. With more-recent versions of TCGA, including the one we were just awarded, we have more of an opportunity to take the lessons of the last 15 years and see how each of those abnormalities explains why some patients respond to cancer treatments and others do not." Dr Neil Hayes, Division Chief, Hematology and Oncology, University of Tennessee Health Science Center Source:

National Cancer Institute Investments

132 Investments

National Cancer Institute has made 132 investments. Their latest investment was in TumorGen as part of their Grant on August 8, 2021.

CBI Logo

National Cancer Institute Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

8/26/2021

Grant

TumorGen

$0.39M

Yes

2

8/12/2021

Grant

Advanced Chemotherapy Technologies

$4M

Yes

2

5/25/2021

Grant

miRecule

$2M

Yes

1

1/25/2021

Grant - II

Subscribe to see more

$99M

Subscribe to see more

10

1/19/2021

Grant - III

Subscribe to see more

$99M

Subscribe to see more

10

Date

8/26/2021

8/12/2021

5/25/2021

1/25/2021

1/19/2021

Round

Grant

Grant

Grant

Grant - II

Grant - III

Company

TumorGen

Advanced Chemotherapy Technologies

miRecule

Subscribe to see more

Subscribe to see more

Amount

$0.39M

$4M

$2M

$99M

$99M

New?

Yes

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

2

1

10

10

National Cancer Institute Portfolio Exits

17 Portfolio Exits

National Cancer Institute has 17 portfolio exits. Their latest portfolio exit was Cyteir Therapeutics on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$991

1

1/10/2020

Acquired

$991

1

7/16/2019

Merger

1

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

6/18/2021

1/10/2020

7/16/2019

00/00/0000

00/00/0000

Exit

IPO

Acquired

Merger

Subscribe to see more

Subscribe to see more

Companies

Subscribe to see more

Subscribe to see more

Valuation

$991

$991

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

National Cancer Institute Partners & Customers

10 Partners and customers

National Cancer Institute has 10 strategic partners and customers. National Cancer Institute recently partnered with Ascentage Pharma on July 7, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

7/19/2021

Partner

Ascentage Pharma

China

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma’s Drug Compound pelcitoclax

Leveraging its robust R&D capabilities , Ascentage Pharma has built a portfolio of global intellectual property rights , and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology , MD Anderson Cancer Center , Mayo Clinic , Dana-Farber Cancer Institute , MSD , and AstraZeneca .

3

5/27/2021

Partner

Sapience Therapeutics

United States

16:30 ET Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Special...

HARRISON , N.Y. , May 27 , 2021 / PRNewswire / -- Sapience Therapeutics , Inc. , a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications , announced today that it has entered into a Collaboration Agreement with the National Cancer Institute of the National Institutes of Health to investigate the activity of its lead clinical program , ST101 , in specialized tumor models developed by the National Cancer Institute .

1

3/23/2021

Vendor

Charles River Analytics

United States

National Cancer Institute Awards Charles River Analytics Funding to Develop Wearable Informatics.

Tozny is thrilled to once again collaborate with Charles River Analytics to bring our innovative and proven encryption and privacy technologies to bear in protecting people and their data .

1

2/24/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

2/3/2021

Partner

Subscribe to see more

Subscribe to see more

Subscribe to see more

10

Date

7/19/2021

5/27/2021

3/23/2021

2/24/2021

2/3/2021

Type

Partner

Partner

Vendor

Partner

Partner

Business Partner

Ascentage Pharma

Sapience Therapeutics

Charles River Analytics

Country

China

United States

United States

Subscribe to see more

Subscribe to see more

News Snippet

Ascentage Pharma Establishes Cooperative R&D Agreement (CRADA) with the National Cancer Institute for Clinical Development of Ascentage Pharma’s Drug Compound pelcitoclax

Leveraging its robust R&D capabilities , Ascentage Pharma has built a portfolio of global intellectual property rights , and entered into global partnerships with numerous renowned biotechnology and pharmaceutical companies and research institutes such as UNITY Biotechnology , MD Anderson Cancer Center , Mayo Clinic , Dana-Farber Cancer Institute , MSD , and AstraZeneca .

16:30 ET Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Special...

HARRISON , N.Y. , May 27 , 2021 / PRNewswire / -- Sapience Therapeutics , Inc. , a biotechnology company focused on the discovery and development of peptide therapeutics to address difficult to treat oncology indications , announced today that it has entered into a Collaboration Agreement with the National Cancer Institute of the National Institutes of Health to investigate the activity of its lead clinical program , ST101 , in specialized tumor models developed by the National Cancer Institute .

National Cancer Institute Awards Charles River Analytics Funding to Develop Wearable Informatics.

Tozny is thrilled to once again collaborate with Charles River Analytics to bring our innovative and proven encryption and privacy technologies to bear in protecting people and their data .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

National Cancer Institute Team

1 Team Member

National Cancer Institute has 1 team member, including former Senior Director, Sue Dubman.

Name

Work History

Title

Status

Sue Dubman

Senior Director

Former

Name

Sue Dubman

Work History

Title

Senior Director

Status

Former

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.